293 related articles for article (PubMed ID: 36209522)
1. Interleukin-1 and the NLRP3 inflammasome in COVID-19: Pathogenetic and therapeutic implications.
Potere N; Del Buono MG; Caricchio R; Cremer PC; Vecchié A; Porreca E; Dalla Gasperina D; Dentali F; Abbate A; Bonaventura A
EBioMedicine; 2022 Nov; 85():104299. PubMed ID: 36209522
[TBL] [Abstract][Full Text] [Related]
2. Spontaneous NLRP3 inflammasome-driven IL-1-β secretion is induced in severe COVID-19 patients and responds to anakinra treatment.
Bertoni A; Penco F; Mollica H; Bocca P; Prigione I; Corcione A; Cangelosi D; Schena F; Del Zotto G; Amaro A; Paladino N; Pontali E; Feasi M; Signa S; Bustaffa M; Caorsi R; Palmeri S; Contini P; De Palma R; Pfeffer U; Uva P; Rubartelli A; Gattorno M; Volpi S
J Allergy Clin Immunol; 2022 Oct; 150(4):796-805. PubMed ID: 35835255
[TBL] [Abstract][Full Text] [Related]
3. Colchicine for COVID-19: targeting NLRP3 inflammasome to blunt hyperinflammation.
Bonaventura A; Vecchié A; Dagna L; Tangianu F; Abbate A; Dentali F
Inflamm Res; 2022 Mar; 71(3):293-307. PubMed ID: 35113170
[TBL] [Abstract][Full Text] [Related]
4. NLRP3 inflammasome and interleukin-1 contributions to COVID-19-associated coagulopathy and immunothrombosis.
Potere N; Garrad E; Kanthi Y; Di Nisio M; Kaplanski G; Bonaventura A; Connors JM; De Caterina R; Abbate A
Cardiovasc Res; 2023 Sep; 119(11):2046-2060. PubMed ID: 37253117
[TBL] [Abstract][Full Text] [Related]
5. Targeting the NLRP3 Inflammasome in Severe COVID-19.
Freeman TL; Swartz TH
Front Immunol; 2020; 11():1518. PubMed ID: 32655582
[TBL] [Abstract][Full Text] [Related]
6. Modulation of the NLRP3 inflammasome by Sars-CoV-2 Envelope protein.
Yalcinkaya M; Liu W; Islam MN; Kotini AG; Gusarova GA; Fidler TP; Papapetrou EP; Bhattacharya J; Wang N; Tall AR
Sci Rep; 2021 Dec; 11(1):24432. PubMed ID: 34952919
[TBL] [Abstract][Full Text] [Related]
7. [Role of inflammasome NLRP3 in the pathophysiology of viral infections: A focus on SARS-CoV-2 infection].
Chemarin M; Dufies O; Mazet A; Mellan E; Coudereau R; Py BF; Boyer L; Venet F
Med Sci (Paris); 2022; 38(6-7):545-552. PubMed ID: 35766852
[TBL] [Abstract][Full Text] [Related]
8. [Progress in the relationship between NLRP3 inflammasome and lung injury in COVID-19].
Ren Z; Che P; Li Z; Mo M; Zhang S; Zhang Y
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2021 Sep; 37(9):844-850. PubMed ID: 34533131
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease.
Abbate A; Toldo S; Marchetti C; Kron J; Van Tassell BW; Dinarello CA
Circ Res; 2020 Apr; 126(9):1260-1280. PubMed ID: 32324502
[TBL] [Abstract][Full Text] [Related]
10. Novel therapeutic targets for SARS-CoV-2-induced acute lung injury: Targeting a potential IL-1β/neutrophil extracellular traps feedback loop.
Yaqinuddin A; Kashir J
Med Hypotheses; 2020 Oct; 143():109906. PubMed ID: 32505910
[TBL] [Abstract][Full Text] [Related]
11. Inflammasomes and IL-1 family cytokines in SARS-CoV-2 infection: from prognostic marker to therapeutic agent.
Declercq J; De Leeuw E; Lambrecht BN
Cytokine; 2022 Sep; 157():155934. PubMed ID: 35709568
[TBL] [Abstract][Full Text] [Related]
12. Comparing the expression of MiR-223-NLRP3-IL-1β axis and serum IL-1β levels in patients with severe COVID-19 and healthy individuals.
Houshmandfar S; Khodadadi A; Mahmoudian-Sani MR; Nashibi R; Rashno M
Immunobiology; 2023 Sep; 228(5):152710. PubMed ID: 37478686
[TBL] [Abstract][Full Text] [Related]
13. The NLRP3 inflammasome and COVID-19: Activation, pathogenesis and therapeutic strategies.
Zhao N; Di B; Xu LL
Cytokine Growth Factor Rev; 2021 Oct; 61():2-15. PubMed ID: 34183243
[TBL] [Abstract][Full Text] [Related]
14. An epithelial-immune circuit amplifies inflammasome and IL-6 responses to SARS-CoV-2.
Barnett KC; Xie Y; Asakura T; Song D; Liang K; Taft-Benz SA; Guo H; Yang S; Okuda K; Gilmore RC; Loome JF; Oguin Iii TH; Sempowski GD; Randell SH; Heise MT; Lei YL; Boucher RC; Ting JP
Cell Host Microbe; 2023 Feb; 31(2):243-259.e6. PubMed ID: 36563691
[TBL] [Abstract][Full Text] [Related]
15. Targeting the NLRP3 inflammasome in cardiovascular diseases.
Toldo S; Mezzaroma E; Buckley LF; Potere N; Di Nisio M; Biondi-Zoccai G; Van Tassell BW; Abbate A
Pharmacol Ther; 2022 Aug; 236():108053. PubMed ID: 34906598
[TBL] [Abstract][Full Text] [Related]
16. Disengaging the COVID-19 Clutch as a Discerning Eye Over the Inflammatory Circuit During SARS-CoV-2 Infection.
Anwar MM; Sah R; Shrestha S; Ozaki A; Roy N; Fathah Z; Rodriguez-Morales AJ
Inflammation; 2022 Oct; 45(5):1875-1894. PubMed ID: 35639261
[TBL] [Abstract][Full Text] [Related]
17. Hydrogen-Rich Saline Attenuated Subarachnoid Hemorrhage-Induced Early Brain Injury in Rats by Suppressing Inflammatory Response: Possible Involvement of NF-κB Pathway and NLRP3 Inflammasome.
Shao A; Wu H; Hong Y; Tu S; Sun X; Wu Q; Zhao Q; Zhang J; Sheng J
Mol Neurobiol; 2016 Jul; 53(5):3462-3476. PubMed ID: 26091790
[TBL] [Abstract][Full Text] [Related]
18. Vitamin D regulates COVID-19 associated severity by suppressing the NLRP3 inflammasome pathway.
Khalil B; Sharif-Askari NS; Hafezi S; Sharif-Askari FS; Al Anouti F; Hamid Q; Halwani R
PLoS One; 2024; 19(5):e0302818. PubMed ID: 38748756
[TBL] [Abstract][Full Text] [Related]
19. Inflammasomes during SARS-CoV-2 infection and development of their corresponding inhibitors.
Diarimalala RO; Wei Y; Hu D; Hu K
Front Cell Infect Microbiol; 2023; 13():1218039. PubMed ID: 37360532
[TBL] [Abstract][Full Text] [Related]
20. Severe COVID-19 patients show a dysregulation of the NLRP3 inflammasome in circulating neutrophils.
Leal VNC; Andrade MMS; Teixeira FME; Cambui RAG; Roa MEGV; Marra LG; Yamada SM; Alberca RW; Gozzi-Silva SC; Yendo TM; Netto LC; Duarte AJS; Sato MN; Pontillo A
Scand J Immunol; 2023 Mar; 97(3):e13247. PubMed ID: 36541819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
